Notre Dame Institute for Global Investing

GordonMD® Invests in Private Placement for Taysha Gene Therapies

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, NOT, Central nervous system, Civil service commission, Investment, RESPECT, Rett syndrome, MECP2, AAV, CNS, Giant axonal neuropathy, Orphan drug, GAN, MD, Risk, ANY, Rare, FDA, Notre Dame Institute for Global Investing, European Commission, Pharmaceutical industry

GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).

Key Points: 
  • GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).
  • Rett syndrome is a rare genetic neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene.
  • TSHA-102 utilizes a novel miRARE platform designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.
  • The firm manages a private fund and a public fund, each focused on differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan.

GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna

Retrieved on: 
Tuesday, August 15, 2023
Biotechnology, Pharmaceutical, Finance, Health, Banking, Professional Services, Genetics, Clinical Trials, Gilead Sciences, NOT, CD19, Investment, RESPECT, Cancer, CAR, MD, Patient, Engineering, Capital, RTW, Lupus nephritis, ANY, Notre Dame Institute for Global Investing, Insight Partners, Pharmaceutical industry

GordonMD® Global Investments LP participated in a $60 million Series B financing round extension for Kyverna Therapeutics, a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases.

Key Points: 
  • GordonMD® Global Investments LP participated in a $60 million Series B financing round extension for Kyverna Therapeutics, a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases.
  • "We are pleased by the increasing investor confidence in the promise of Kyverna's anti-CD19 CAR T-cell therapy for autoimmune diseases," said Ryan Jones, chief financial officer of Kyverna.
  • Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD® Global Investments said: "I have supported anti-CD19 CAR T-cell therapy for cancer since the early clinical trials.
  • It is exciting to see Kyverna break into new frontiers by advancing cell therapies for autoimmune diseases.

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Retrieved on: 
Monday, September 12, 2022
Software, Biotechnology, General Health, Health, Data Management, Health Technology, Technology, Genetics, Therapy, Gene editing, Chemical engineering, CRISPR, CIO, Therapeutic Targets Database, Senior, Acquisition, Growth, Industry, Berkeley, CEO, MBA, Amgen, Cancer, Nanotechnology, Notre Dame Institute for Global Investing, 5, Biotechnology, University of Washington Department of Bioengineering, Hemoglobinopathy, Multimedia, University, Management, Medical device, Pharmaceutical industry, Spotlight

Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.

Key Points: 
  • Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220912005015/en/
    "We are delighted to welcome Arvind to Spotlights leadership team.
  • "Arvind has deep experience in biologics and will play a key role in helping Spotlight bring a new class of CRISPR ribonucleoprotein therapeutics to patients.
  • Established in 2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies.

TCW Appoints Kathryn Koch as President and Chief Executive Officer

Retrieved on: 
Tuesday, September 6, 2022
Professional Services, Business, Finance, Asset Management, Consulting, Banking, Literature, University, CEO, TCW, TCW Group, Investment fund, Goldman Sachs, Optimism, Spence School, Notre Dame, Organization, Goal, TIFF, Notre Dame Institute for Global Investing, Goldman Sachs asset management factor model, Carole Toïgo, Partner, Notre Dame Institute, Leadership, Trustee, Koch, AMD, Acquisition, Growth, Lists of companies, Management, Security (finance), Financial services, Foundation, Economics

The TCW Group, a global independent asset management firm, today announced the appointment of Kathryn (Katie) Koch as President and Chief Executive Officer.

Key Points: 
  • The TCW Group, a global independent asset management firm, today announced the appointment of Kathryn (Katie) Koch as President and Chief Executive Officer.
  • Koch, 42, joins TCW after 20 years with Goldman Sachs in the Asset Management Division (AMD), where she was a Partner and most recently served as Chief Investment Officer of the $300 billion Public Equity business and as a member of the AMD executive committee.
  • I am humbled and grateful for the opportunity to lead a company with the strong heritage and bright future of TCW, said Koch.
  • Koch will succeed current President and CEO David Lippman, who, as planned and previously reported, will retire from TCW at the end of 2022.

Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member

Retrieved on: 
Tuesday, July 12, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Oncology, SVP, Therapeutic Targets Database, Biotechnology, Multimedia, Breast cancer, Development, Johnson & Johnson, Rhône-Poulenc, Daiichi Sankyo, Gene editing, Science, Leadership, Therapy, CRISPR, Patient, CEO, Notre Dame Institute for Global Investing, AstraZeneca, Director, CIO, Hemoglobinopathy, Board, Industry, Drug development, Merck, Vaccine, Pharmaceutical industry, Spotlight, Sanofi

Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Antoine Yver, M.D., M.Sc.

Key Points: 
  • Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Antoine Yver, M.D., M.Sc.
  • View the full release here: https://www.businesswire.com/news/home/20220704005433/en/
    We are thrilled to welcome Antoine to Spotlights Board of Directors, said Mary Haak-Frendscho, Ph.D., President and Chief Executive Officer of Spotlight.
  • Antoines deep insights and vast global pharma experience will help propel Spotlight to becoming a clinical stage company, said Craig Gordon, M.D., Spotlight board member, Founder, CEO, and CIO of GordonMD Global Investments.
  • Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies.

VISPARK Launches Spark Math and Spark Chinese Online Learning Programs in the U.S.

Retrieved on: 
Tuesday, June 21, 2022
Cognitive science, Culture, Learning, Environment, CCSS, Technology, GGV Capital, Notre Dame Institute for Global Investing, IDG Capital, KKR, Student, Ageing, Problem solving, Interactive Mathematics Program, Program, Common Core State Standards Initiative, Education, History, Kid Spark Education, Multimedia, Language, SAN, Mathematics, Tutoring

SAN MATEO, Calif., June 21, 2022 /PRNewswire/ --VISPARK, a global online learning service designed for kids from preschool to middle school, is launching the Spark Math and Spark Chinese programs ("the Programs") in the U.S. this month.

Key Points: 
  • SAN MATEO, Calif., June 21, 2022 /PRNewswire/ --VISPARK, a global online learning service designed for kids from preschool to middle school, is launching the Spark Math and Spark Chinese programs ("the Programs") in the U.S. this month.
  • VISPARK's programs build upon the experiences from the company's success using Huohua Siwei, an online learning service Spark Education designed for Chinese-speaking families.
  • The two new programs from VISPARK, Spark Math and Spark Chinese, have been developed with best practices from decades of pedagogy research, cognitive science, and child-centered curriculum development.
  • Spark Education's math programs have gained popularity and demonstrated strong results with its students in Singapore excelling in various international math competitions.